Avidity Partners Management LP Aurinia Pharmaceuticals Inc. Transaction History

Avidity Partners Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $17.8 Million - $25.9 Million	-1,784,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $2.66 Million - $4.05 Million	-216,000 Reduced 10.8%	1,784,000 $23.2 Million
Q4 2020 Feb 16, 2021	SELL	$12.94 - $16.05 $20.2 Million - $25.1 Million	-1,564,900 Reduced 43.9%	2,000,000 $27.7 Million
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $14.4 Million - $18.2 Million	1,090,301 Added 44.06%	3,564,900 $52.5 Million
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $18.3 Million - $23.7 Million	1,292,599 Added 109.36%	2,474,599 $40.2 Million
Q1 2020 Jun 17, 2020	BUY	$11.34 - $21.46 $13.4 Million - $25.4 Million	1,182,000 New	1,182,000 $17.2 Million
Q1 2020 May 15, 2020	SELL	$11.34 - $21.46 $2.63 Million - $4.98 Million	-232,000 Closed	0 $0
Q4 2019 Jun 17, 2020	BUY	$3.88 - $21.42 $900,160 - $4.97 Million	232,000 New	232,000 $4.7 Million

214

58.3M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.